HOME
ABOUT US
SOCIAL IMPACT
STRATEGY
GENE THERAPY
CELL THERAPY
RNA-BASED THERAPY
TARGETED THERAPIES
MICROBIOME
TEAM
PORTFOLIO
VENTURE PORTFOLIO
PAST PORTFOLIO
4BATLE ICAV
NEWS ROOM
CONTACT
More
Use tab to navigate through the menu items.
NEWS ROOM
Mar 24, 2018
TiGenix and Takeda announce Alofisel® (darvadstrocel) receives approval
Jan 5, 2018
Takeda announces its intention to acquire TiGenix
ARCHIVE
April 2022
March 2022
February 2022
January 2022
December 2021
October 2021
April 2021
March 2021
January 2021
December 2020
November 2020
October 2020
July 2020
June 2020
May 2020
March 2020
November 2019
September 2019
February 2019
November 2018
SEARCH BY TAGS
portfolio
4BIO Ventures II
Orchard Therapeutics
appointment
investment
approval
collaboration
advisory board
SparingVision
Spark Therapeutics
Takeda
AAV
acquisition
ADC Therapeutics
CodeBio
IPO
publication
Ray Therapeutics
review
TiGenix
4BATLE
AI
awards
BLA
Carisma
clinical trials
EGLS
ETF
grant
Harbor Capital
Insig AI
Intellia
Kyowa Kirin
Moderna
pricing
Redpin Therapeutics
results
venture
FOLLOW US